Thyroid tumorigenesis and molecular markers in thyroid cancer

Guennadi Kouniavsky, Martha A. Zeiger

Research output: Contribution to journalArticle

Abstract

Purpose of review The purpose of this review is to provide an update on recent advances in the understanding of thyroid cancer tumorigensis and implications in clinical practice. Recent findings: Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-β-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities. Complex regulatory mechanisms and insights into ways in which molecular aberrancies occur are becoming better understood through this research. Summary: With ongoing research, clinical problems such as the suspicious thyroid fine needle aspiration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatment for anaplastic cancer will likely be found.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalCurrent Opinion in Oncology
Volume22
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Thyroid Neoplasms
Thyroid Gland
Carcinogenesis
Mitogen-Activated Protein Kinase Kinases
Alternative Splicing
Fine Needle Biopsy
Phosphatidylinositol 3-Kinases
Research
Epigenomics
Single Nucleotide Polymorphism
Gene Expression
Therapeutics
Neoplasms

Keywords

  • Alternative splicing
  • Gene rearrangement
  • Molecular abnormalities
  • Single-nucleotide polymorphisms
  • Thyroid tumorigenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thyroid tumorigenesis and molecular markers in thyroid cancer. / Kouniavsky, Guennadi; Zeiger, Martha A.

In: Current Opinion in Oncology, Vol. 22, No. 1, 01.2010, p. 23-29.

Research output: Contribution to journalArticle

Kouniavsky, Guennadi ; Zeiger, Martha A. / Thyroid tumorigenesis and molecular markers in thyroid cancer. In: Current Opinion in Oncology. 2010 ; Vol. 22, No. 1. pp. 23-29.
@article{1aa242d075854990a8f0e2e3059bf5db,
title = "Thyroid tumorigenesis and molecular markers in thyroid cancer",
abstract = "Purpose of review The purpose of this review is to provide an update on recent advances in the understanding of thyroid cancer tumorigensis and implications in clinical practice. Recent findings: Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-β-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities. Complex regulatory mechanisms and insights into ways in which molecular aberrancies occur are becoming better understood through this research. Summary: With ongoing research, clinical problems such as the suspicious thyroid fine needle aspiration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatment for anaplastic cancer will likely be found.",
keywords = "Alternative splicing, Gene rearrangement, Molecular abnormalities, Single-nucleotide polymorphisms, Thyroid tumorigenesis",
author = "Guennadi Kouniavsky and Zeiger, {Martha A.}",
year = "2010",
month = "1",
doi = "10.1097/CCO.0b013e328333846f",
language = "English (US)",
volume = "22",
pages = "23--29",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Thyroid tumorigenesis and molecular markers in thyroid cancer

AU - Kouniavsky, Guennadi

AU - Zeiger, Martha A.

PY - 2010/1

Y1 - 2010/1

N2 - Purpose of review The purpose of this review is to provide an update on recent advances in the understanding of thyroid cancer tumorigensis and implications in clinical practice. Recent findings: Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-β-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities. Complex regulatory mechanisms and insights into ways in which molecular aberrancies occur are becoming better understood through this research. Summary: With ongoing research, clinical problems such as the suspicious thyroid fine needle aspiration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatment for anaplastic cancer will likely be found.

AB - Purpose of review The purpose of this review is to provide an update on recent advances in the understanding of thyroid cancer tumorigensis and implications in clinical practice. Recent findings: Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-β-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities. Complex regulatory mechanisms and insights into ways in which molecular aberrancies occur are becoming better understood through this research. Summary: With ongoing research, clinical problems such as the suspicious thyroid fine needle aspiration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatment for anaplastic cancer will likely be found.

KW - Alternative splicing

KW - Gene rearrangement

KW - Molecular abnormalities

KW - Single-nucleotide polymorphisms

KW - Thyroid tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=73849134974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849134974&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328333846f

DO - 10.1097/CCO.0b013e328333846f

M3 - Article

C2 - 19907326

AN - SCOPUS:73849134974

VL - 22

SP - 23

EP - 29

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -